![]() |
JOURNAL TOOLS |
Publishing options |
eTOC |
To subscribe |
Submit an article |
Recommend to your librarian |
ARTICLE TOOLS |
Publication history |
Reprints |
Permissions |
Cite this article as |
Share |


YOUR ACCOUNT
YOUR ORDERS
SHOPPING BASKET
Items: 0
Total amount: € 0,00
HOW TO ORDER
YOUR SUBSCRIPTIONS
YOUR ARTICLES
YOUR EBOOKS
COUPON
ACCESSIBILITY
REVIEW
Minerva Gastroenterologica e Dietologica 2019 March;65(1):42-52
DOI: 10.23736/S1121-421X.18.02525-4
Copyright © 2018 EDIZIONI MINERVA MEDICA
language: English
Diverticulosis today
Walter ELISEI 1, Giovanni BRANDIMARTE 2, Antonio TURSI 3 ✉
1 Division of Gastroenterology, ASL Roma 6, Albano Laziale, Rome, Italy; 2 Division of Internal Medicine and Gastroenterology, Cristo Re Hospital, Rome, Italy; 3 Service of Gastroenterology, ASL BAT, Andria, Italy
The incidence of diverticulosis and diverticular disease of the colon is increasing worldwide. Although the majority of patients remains asymptomatic long-life, the prevalence of diverticular disease of the colon, including acute diverticulitis, is substantial and is becoming a significant burden on National Health Systems in terms of direct and indirect costs. Fiber, non-absorbable antibiotics and probiotics seem to be effective in treating symptomatic and uncomplicated patients, and 5-aminosalicylic acid might help prevent acute diverticulitis. Unfortunately, robust evidence on the effectiveness of a medical strategy to prevent acute diverticulitis recurrence is still lacking. Focus is now being drawn on identifying a new endoscopic classification of the disease to evaluate the correct therapeutic approach by testing various treatments.
KEY WORDS: Diverticular diseases - Colonic diverticulosis - Mesalamine - Colonic diverticulitis - Probiotics